Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:VEZF1-KRT222 (FusionGDB2 ID:97381)

Fusion Gene Summary for VEZF1-KRT222

Fusion gene summary

Fusion gene information	Fusion gene name: VEZF1-KRT222
	Fusion gene ID: 97381
		Hgene	Tgene
	Gene symbol	VEZF1	KRT222
	Gene ID	7716	125113
	Gene name	vascular endothelial zinc finger 1	keratin 222
	Synonyms	DB1\|ZNF161	KA21\|KRT222P
	Cytomap	17q22	17q21.2
	Type of gene	protein-coding	protein-coding
	Description	vascular endothelial zinc finger 1putative transcription factor DB1zinc finger protein 161	keratin-like protein KRT222keratin 222, type IIkeratin-222 pseudogene
	Modification date	20200313	20200313
	UniProtAcc	.	.
	Ensembl transtripts involved in fusion gene	ENST00000584396, ENST00000581208,	ENST00000476049, ENST00000394052,
Fusion gene scores	* DoF score	5 X 4 X 5=100	7 X 5 X 5=175
	# samples	6	10
	** MAII score	log2(6/100*10)=-0.736965594166206 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(10/175*10)=-0.807354922057604 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: VEZF1 [Title/Abstract] AND KRT222 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	VEZF1(56065440)-KRT222(38816459), # samples:3
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	VEZF1	GO:0045944	positive regulation of transcription by RNA polymerase II	11504723

Fusion gene breakpoints across VEZF1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across KRT222 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	ESCA	TCGA-JY-A6FB	VEZF1	chr17	56065439	-	KRT222	chr17	38816459	-
ChimerDB4	ESCA	TCGA-JY-A6FB	VEZF1	chr17	56065439	-	KRT222	chr17	38816459	-
ChimerDB4	ESCA	TCGA-JY-A6FB	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-
ChimerDB4	ESCA	TCGA-JY-A6FB	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-
ChimerDB4	ESCA	TCGA-JY-A6FB-01A	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-

Top

Fusion Gene ORF analysis for VEZF1-KRT222

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
intron-3CDS	ENST00000584396	ENST00000476049	VEZF1	chr17	56065439	-	KRT222	chr17	38816459	-
intron-3CDS	ENST00000584396	ENST00000394052	VEZF1	chr17	56065439	-	KRT222	chr17	38816459	-
In-frame	ENST00000581208	ENST00000476049	VEZF1	chr17	56065439	-	KRT222	chr17	38816459	-
In-frame	ENST00000581208	ENST00000394052	VEZF1	chr17	56065439	-	KRT222	chr17	38816459	-
intron-3CDS	ENST00000584396	ENST00000476049	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-
intron-3CDS	ENST00000584396	ENST00000394052	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-
In-frame	ENST00000581208	ENST00000476049	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-
In-frame	ENST00000581208	ENST00000394052	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000581208	VEZF1	chr17	56065439	-	ENST00000476049	KRT222	chr17	38816459	-	2309	74	1289	2308	340
ENST00000581208	VEZF1	chr17	56065439	-	ENST00000394052	KRT222	chr17	38816459	-	909	74	41	736	231
ENST00000581208	VEZF1	chr17	56065440	-	ENST00000476049	KRT222	chr17	38816459	-	2309	74	1289	2308	340
ENST00000581208	VEZF1	chr17	56065440	-	ENST00000394052	KRT222	chr17	38816459	-	909	74	41	736	231

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000581208	ENST00000476049	VEZF1	chr17	56065439	-	KRT222	chr17	38816459	-	0.006988693	0.9930113
ENST00000581208	ENST00000394052	VEZF1	chr17	56065439	-	KRT222	chr17	38816459	-	0.002929821	0.9970702
ENST00000581208	ENST00000476049	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-	0.006988693	0.9930113
ENST00000581208	ENST00000394052	VEZF1	chr17	56065440	-	KRT222	chr17	38816459	-	0.002929821	0.9970702

Top

Fusion Genomic Features for VEZF1-KRT222

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for VEZF1-KRT222

Go to
FGviewer for the breakpoints of chr17:56065439-chr17:38816459
.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
.	.
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.	FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

340_354

11.0

522.0

Compositional bias

Note=Poly-Gln

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

340_354

11.0

522.0

Compositional bias

Note=Poly-Gln

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

394_485

11.0

522.0

Region

Note=4 X 7 AA repeats of P-[LV]-T-[IL]-T-[ST]-P

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

394_485

11.0

522.0

Region

Note=4 X 7 AA repeats of P-[LV]-T-[IL]-T-[ST]-P

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

394_400

11.0

522.0

Repeat

Note=1

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

445_451

11.0

522.0

Repeat

Note=2

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

457_463

11.0

522.0

Repeat

Note=3

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

479_485

11.0

522.0

Repeat

Note=4

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

394_400

11.0

522.0

Repeat

Note=1

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

445_451

11.0

522.0

Repeat

Note=2

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

457_463

11.0

522.0

Repeat

Note=3

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

479_485

11.0

522.0

Repeat

Note=4

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

174_196

11.0

522.0

Zinc finger

C2H2-type 2

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

202_224

11.0

522.0

Zinc finger

C2H2-type 3

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

232_255

11.0

522.0

Zinc finger

C2H2-type 4

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

261_283

11.0

522.0

Zinc finger

C2H2-type 5

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

287_308

11.0

522.0

Zinc finger

C2H2-type 6

Hgene

VEZF1

chr17:56065439

chr17:38816459

ENST00000581208

74_96

11.0

522.0

Zinc finger

C2H2-type 1

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

174_196

11.0

522.0

Zinc finger

C2H2-type 2

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

202_224

11.0

522.0

Zinc finger

C2H2-type 3

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

232_255

11.0

522.0

Zinc finger

C2H2-type 4

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

261_283

11.0

522.0

Zinc finger

C2H2-type 5

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

287_308

11.0

522.0

Zinc finger

C2H2-type 6

Hgene

VEZF1

chr17:56065440

chr17:38816459

ENST00000581208

74_96

11.0

522.0

Zinc finger

C2H2-type 1

Tgene

KRT222

chr17:56065439

chr17:38816459

ENST00000394052

2_150

75.0

296.0

Coiled coil

Ontology_term=ECO:0000255

Tgene

KRT222

chr17:56065440

chr17:38816459

ENST00000394052

2_150

75.0

296.0

Coiled coil

Ontology_term=ECO:0000255

Tgene

KRT222

chr17:56065439

chr17:38816459

ENST00000394052

1_150

75.0

296.0

Domain

IF rod

Tgene

KRT222

chr17:56065440

chr17:38816459

ENST00000394052

1_150

75.0

296.0

Domain

IF rod

Top

Fusion Gene Sequence for VEZF1-KRT222

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>In-frame_ENST00000581208_ENST00000476049_TCGA-JY-A6FB_VEZF1_chr17_56065439_-_KRT222_chr17_38816459_length(transcript)=2309nt_BP=74nt
AGCGGGGGGAGTGGGGAGGAGGGGGGTCGGCCGCCGCAGCCATGGAGGCCAACTGGACCGCGTTCCTGTTCCAGGAAAGGGGCCTTGAAA
ACTCCCTACATGCCAGCGAGCAGCATTACCAGATGCAGCTGCAAGACCTAGAGACTGTGATTGAAGGACTAGAAAAAGAGCTACAGGAAG
TAAGGCGCGGCATCGAAAAGCAGCTTCAAGAGCACGAGATGCTTCTCAACACGAAGATGAGGCTGGAACAAGAAATAGCAACTTATCGCC
ACCTCCTAGAAAAAGAAGAAATCAGATATTATGGTTGTATCCAAGGTGGGAAAAAAGACAAAAAGCCTACCACAAGTAGAGTTGGTTTTG
TTTTACCATCAGCCATTATAAATGAAATATCTTTTACTACAAAAGTCCCACAAAAGTATGAGAATGAAAATGTAGAAACAGTAACCAAAC
AGGCAATCTTAAATGGGAGTATCGTTAAGGAGAGCACTGAAGCTCATGGCACTATTCAGACAGAGAAAGTGGATGAAGTTATTAAAGAAT
GGGAAGGTTCTTTCTTTAAAGATAACCCTCGATTGAGGAAAAAGTCTGTTTCTCTTCGATTTGATCTTCATTTAGCAGCCACTGATGAAG
GGTGTTTAGAGACTAAGCAGGATAATCTACCAGATATAGAAGTCAGGCTTATCATGAGAAGATCATGCAGTATTCCCTCTATCAAACCTC
CATCAACAGCTAATTAATCCAAAGATAGTATTTGACTTGATTGGAAAATGTTAGGATGGACCAAGGTGGGCCATACCAACTCCCTCTGTC
CCAAAATTAACCACAGGTCAGGGATCCCATACGTTCATTCTCCCTCCACAGTGACCCACAATATCCATCGGGTGTTTATGTATCCAAAGA
AGAGGCTACTCATTCCATCTGGTAAACCAACATACTCATGATTTAGTGGAAAGAGCCCTGGAGTGGCACAGAGGGCTGCCTCAATACACA
CTTACTGAGCGTCTAACAATGAATGGGTCAAGCCCTTCGTAGGCACTGGCAATGGGAAGATGACCAATACAGACGGCTGAACCTTGCTTT
CAAGGCCTTCATAAAGCACTGGAGATGACAAACACGGTCCGATACAAAGGGTCGGGTTCAGGACTCCAACCATTATTATCAAAGAGCCAC
GGGAATACAAAGGAAGGATTACTAGGGGGGAAGTTCCAGGAGGGCATCACAAAGAGACCTCTGAGCTGGATCCAGAAGGACAGATGAGTT
TAAGCTGAAAGTGGGGACGGTCGTTCCCGCTGGTGGGAACCGAAGGAGCCGAGGCAGCGCTGAGGCGGAGACCAGTAAAGGCTTCCAACC
CTGACCTAAAGTTGTGGGAGATTGGCAAGATTATTGGTGGCATGTGGCGAGATCTCACTGATGAAGAAAAACAAGAATATTTAAACGAAT
ACGAAGCAGAAAAGATAGAGTACAATGAATCTATGAAGGCCTATCATAATTCCCCCGCGTACCTTGCTTACATAAATGCAAAAAGTCGTG
CAGAAGCTGCTTTAGAGGAAGAAAGTCGACAGAGACAATCTCGCATGGAGAAAGGAGAACCGTACATGAGCATTCAGCCTGCTGAAGATC
CAGATGATTATGATGATGGCTTTTCAATGAAGCATACAGCCACCGCCCGTTTCCAGAGAAACCACCGCCTCATCAGTGAAATTCTTAGTG
AGAGTGTGGTGCCAGACGTTCGGTCAGTTGTCACAACAGCTAGAATGCAGGTCCTCAAACGGCAGGTCCAGTCCTTAATGGTTCATCAGC
GAAAACTAGAAGCTGAACTTCTTCAAATAGAGGAACGACACCAGGAGAAGAAGAGGAAATTCCTGGAAAGCACAGATTCATTTAACAATG
AACTTAAAAGGTTGTGCGGTCTGAAAGTAGAAGTGGATATGGAGAAAATTGCAGCTGAGATTGCACAGGCAGAGGAACAGGCCCGCAAAA
GGCAGGAGGAAAGGGAGAAGGAGGCCGCAGAGCAAGCTGAGCGCAGTCAGAGCAGCATCGTTCCTGAGGAAGAACAAGCAGCTAACAAAG
GCGAGGAGAAGAAAGACGACGAGAACATTCCGATGGAGACAGAGGAGACACACCTTGAAGAAACAACAGAGAGCCAACAGAATGGTGAAG
AAGGCACGTCTACTCCTGAGGACAAGGAGAGTGGGCAGGAGGGGGTCGACAGTATGGCAGAGGAAGGAACCAGTGATAGTAACACTGGCT

>In-frame_ENST00000581208_ENST00000476049_TCGA-JY-A6FB_VEZF1_chr17_56065439_-_KRT222_chr17_38816459_length(amino acids)=340AA_start in transcript=1289_stop in transcript=2308
MVGTEGAEAALRRRPVKASNPDLKLWEIGKIIGGMWRDLTDEEKQEYLNEYEAEKIEYNESMKAYHNSPAYLAYINAKSRAEAALEEESR
QRQSRMEKGEPYMSIQPAEDPDDYDDGFSMKHTATARFQRNHRLISEILSESVVPDVRSVVTTARMQVLKRQVQSLMVHQRKLEAELLQI
EERHQEKKRKFLESTDSFNNELKRLCGLKVEVDMEKIAAEIAQAEEQARKRQEEREKEAAEQAERSQSSIVPEEEQAANKGEEKKDDENI

--------------------------------------------------------------
>In-frame_ENST00000581208_ENST00000394052_TCGA-JY-A6FB_VEZF1_chr17_56065439_-_KRT222_chr17_38816459_length(transcript)=909nt_BP=74nt
AGCGGGGGGAGTGGGGAGGAGGGGGGTCGGCCGCCGCAGCCATGGAGGCCAACTGGACCGCGTTCCTGTTCCAGGAAAGGGGCCTTGAAA
ACTCCCTACATGCCAGCGAGCAGCATTACCAGATGCAGCTGCAAGACCTAGAGACTGTGATTGAAGGACTAGAAAAAGAGCTACAGGAAG
TAAGGCGCGGCATCGAAAAGCAGCTTCAAGAGCACGAGATGCTTCTCAACACGAAGATGAGGCTGGAACAAGAAATAGCAACTTATCGCC
ACCTCCTAGAAAAAGAAGAAATCAGATATTATGGTTGTATCCAAGGTGGGAAAAAAGACAAAAAGCCTACCACAAGTAGAGTTGGTTTTG
TTTTACCATCAGCCATTATAAATGAAATATCTTTTACTACAAAAGTCCCACAAAAGTATGAGAATGAAAATGTAGAAACAGTAACCAAAC
AGGCAATCTTAAATGGGAGTATCGTTAAGGAGAGCACTGAAGCTCATGGCACTATTCAGACAGAGAAAGTGGATGAAGTTATTAAAGAAT
GGGAAGGTTCTTTCTTTAAAGATAACCCTCGATTGAGGAAAAAGTCTGTTTCTCTTCGATTTGATCTTCATTTAGCAGCCACTGATGAAG
GGTGTTTAGAGACTAAGCAGGATAATCTACCAGATATAGAAGTCAGGCTTATCATGAGAAGATCATGCAGTATTCCCTCTATCAAACCTC
CATCAACAGCTAATTAATCCAAAGATAGTATTTGACTTGATTGGAAAATGTTAGGATGGACCAAGGTGGGCCATACCAACTCCCTCTGTC
CCAAAATGTAAGTTATTACGTATGTATGGAAAATGTTATGATCAATATGTGGTTCTCTTCAGAAGAAAAAAACAATAAAGGACATTTCTC

>In-frame_ENST00000581208_ENST00000394052_TCGA-JY-A6FB_VEZF1_chr17_56065439_-_KRT222_chr17_38816459_length(amino acids)=231AA_start in transcript=41_stop in transcript=736
MEANWTAFLFQERGLENSLHASEQHYQMQLQDLETVIEGLEKELQEVRRGIEKQLQEHEMLLNTKMRLEQEIATYRHLLEKEEIRYYGCI
QGGKKDKKPTTSRVGFVLPSAIINEISFTTKVPQKYENENVETVTKQAILNGSIVKESTEAHGTIQTEKVDEVIKEWEGSFFKDNPRLRK

--------------------------------------------------------------
>In-frame_ENST00000581208_ENST00000476049_TCGA-JY-A6FB_VEZF1_chr17_56065440_-_KRT222_chr17_38816459_length(transcript)=2309nt_BP=74nt
AGCGGGGGGAGTGGGGAGGAGGGGGGTCGGCCGCCGCAGCCATGGAGGCCAACTGGACCGCGTTCCTGTTCCAGGAAAGGGGCCTTGAAA
ACTCCCTACATGCCAGCGAGCAGCATTACCAGATGCAGCTGCAAGACCTAGAGACTGTGATTGAAGGACTAGAAAAAGAGCTACAGGAAG
TAAGGCGCGGCATCGAAAAGCAGCTTCAAGAGCACGAGATGCTTCTCAACACGAAGATGAGGCTGGAACAAGAAATAGCAACTTATCGCC
ACCTCCTAGAAAAAGAAGAAATCAGATATTATGGTTGTATCCAAGGTGGGAAAAAAGACAAAAAGCCTACCACAAGTAGAGTTGGTTTTG
TTTTACCATCAGCCATTATAAATGAAATATCTTTTACTACAAAAGTCCCACAAAAGTATGAGAATGAAAATGTAGAAACAGTAACCAAAC
AGGCAATCTTAAATGGGAGTATCGTTAAGGAGAGCACTGAAGCTCATGGCACTATTCAGACAGAGAAAGTGGATGAAGTTATTAAAGAAT
GGGAAGGTTCTTTCTTTAAAGATAACCCTCGATTGAGGAAAAAGTCTGTTTCTCTTCGATTTGATCTTCATTTAGCAGCCACTGATGAAG
GGTGTTTAGAGACTAAGCAGGATAATCTACCAGATATAGAAGTCAGGCTTATCATGAGAAGATCATGCAGTATTCCCTCTATCAAACCTC
CATCAACAGCTAATTAATCCAAAGATAGTATTTGACTTGATTGGAAAATGTTAGGATGGACCAAGGTGGGCCATACCAACTCCCTCTGTC
CCAAAATTAACCACAGGTCAGGGATCCCATACGTTCATTCTCCCTCCACAGTGACCCACAATATCCATCGGGTGTTTATGTATCCAAAGA
AGAGGCTACTCATTCCATCTGGTAAACCAACATACTCATGATTTAGTGGAAAGAGCCCTGGAGTGGCACAGAGGGCTGCCTCAATACACA
CTTACTGAGCGTCTAACAATGAATGGGTCAAGCCCTTCGTAGGCACTGGCAATGGGAAGATGACCAATACAGACGGCTGAACCTTGCTTT
CAAGGCCTTCATAAAGCACTGGAGATGACAAACACGGTCCGATACAAAGGGTCGGGTTCAGGACTCCAACCATTATTATCAAAGAGCCAC
GGGAATACAAAGGAAGGATTACTAGGGGGGAAGTTCCAGGAGGGCATCACAAAGAGACCTCTGAGCTGGATCCAGAAGGACAGATGAGTT
TAAGCTGAAAGTGGGGACGGTCGTTCCCGCTGGTGGGAACCGAAGGAGCCGAGGCAGCGCTGAGGCGGAGACCAGTAAAGGCTTCCAACC
CTGACCTAAAGTTGTGGGAGATTGGCAAGATTATTGGTGGCATGTGGCGAGATCTCACTGATGAAGAAAAACAAGAATATTTAAACGAAT
ACGAAGCAGAAAAGATAGAGTACAATGAATCTATGAAGGCCTATCATAATTCCCCCGCGTACCTTGCTTACATAAATGCAAAAAGTCGTG
CAGAAGCTGCTTTAGAGGAAGAAAGTCGACAGAGACAATCTCGCATGGAGAAAGGAGAACCGTACATGAGCATTCAGCCTGCTGAAGATC
CAGATGATTATGATGATGGCTTTTCAATGAAGCATACAGCCACCGCCCGTTTCCAGAGAAACCACCGCCTCATCAGTGAAATTCTTAGTG
AGAGTGTGGTGCCAGACGTTCGGTCAGTTGTCACAACAGCTAGAATGCAGGTCCTCAAACGGCAGGTCCAGTCCTTAATGGTTCATCAGC
GAAAACTAGAAGCTGAACTTCTTCAAATAGAGGAACGACACCAGGAGAAGAAGAGGAAATTCCTGGAAAGCACAGATTCATTTAACAATG
AACTTAAAAGGTTGTGCGGTCTGAAAGTAGAAGTGGATATGGAGAAAATTGCAGCTGAGATTGCACAGGCAGAGGAACAGGCCCGCAAAA
GGCAGGAGGAAAGGGAGAAGGAGGCCGCAGAGCAAGCTGAGCGCAGTCAGAGCAGCATCGTTCCTGAGGAAGAACAAGCAGCTAACAAAG
GCGAGGAGAAGAAAGACGACGAGAACATTCCGATGGAGACAGAGGAGACACACCTTGAAGAAACAACAGAGAGCCAACAGAATGGTGAAG
AAGGCACGTCTACTCCTGAGGACAAGGAGAGTGGGCAGGAGGGGGTCGACAGTATGGCAGAGGAAGGAACCAGTGATAGTAACACTGGCT

>In-frame_ENST00000581208_ENST00000476049_TCGA-JY-A6FB_VEZF1_chr17_56065440_-_KRT222_chr17_38816459_length(amino acids)=340AA_start in transcript=1289_stop in transcript=2308
MVGTEGAEAALRRRPVKASNPDLKLWEIGKIIGGMWRDLTDEEKQEYLNEYEAEKIEYNESMKAYHNSPAYLAYINAKSRAEAALEEESR
QRQSRMEKGEPYMSIQPAEDPDDYDDGFSMKHTATARFQRNHRLISEILSESVVPDVRSVVTTARMQVLKRQVQSLMVHQRKLEAELLQI
EERHQEKKRKFLESTDSFNNELKRLCGLKVEVDMEKIAAEIAQAEEQARKRQEEREKEAAEQAERSQSSIVPEEEQAANKGEEKKDDENI

--------------------------------------------------------------
>In-frame_ENST00000581208_ENST00000394052_TCGA-JY-A6FB_VEZF1_chr17_56065440_-_KRT222_chr17_38816459_length(transcript)=909nt_BP=74nt
AGCGGGGGGAGTGGGGAGGAGGGGGGTCGGCCGCCGCAGCCATGGAGGCCAACTGGACCGCGTTCCTGTTCCAGGAAAGGGGCCTTGAAA
ACTCCCTACATGCCAGCGAGCAGCATTACCAGATGCAGCTGCAAGACCTAGAGACTGTGATTGAAGGACTAGAAAAAGAGCTACAGGAAG
TAAGGCGCGGCATCGAAAAGCAGCTTCAAGAGCACGAGATGCTTCTCAACACGAAGATGAGGCTGGAACAAGAAATAGCAACTTATCGCC
ACCTCCTAGAAAAAGAAGAAATCAGATATTATGGTTGTATCCAAGGTGGGAAAAAAGACAAAAAGCCTACCACAAGTAGAGTTGGTTTTG
TTTTACCATCAGCCATTATAAATGAAATATCTTTTACTACAAAAGTCCCACAAAAGTATGAGAATGAAAATGTAGAAACAGTAACCAAAC
AGGCAATCTTAAATGGGAGTATCGTTAAGGAGAGCACTGAAGCTCATGGCACTATTCAGACAGAGAAAGTGGATGAAGTTATTAAAGAAT
GGGAAGGTTCTTTCTTTAAAGATAACCCTCGATTGAGGAAAAAGTCTGTTTCTCTTCGATTTGATCTTCATTTAGCAGCCACTGATGAAG
GGTGTTTAGAGACTAAGCAGGATAATCTACCAGATATAGAAGTCAGGCTTATCATGAGAAGATCATGCAGTATTCCCTCTATCAAACCTC
CATCAACAGCTAATTAATCCAAAGATAGTATTTGACTTGATTGGAAAATGTTAGGATGGACCAAGGTGGGCCATACCAACTCCCTCTGTC
CCAAAATGTAAGTTATTACGTATGTATGGAAAATGTTATGATCAATATGTGGTTCTCTTCAGAAGAAAAAAACAATAAAGGACATTTCTC

>In-frame_ENST00000581208_ENST00000394052_TCGA-JY-A6FB_VEZF1_chr17_56065440_-_KRT222_chr17_38816459_length(amino acids)=231AA_start in transcript=41_stop in transcript=736
MEANWTAFLFQERGLENSLHASEQHYQMQLQDLETVIEGLEKELQEVRRGIEKQLQEHEMLLNTKMRLEQEIATYRHLLEKEEIRYYGCI
QGGKKDKKPTTSRVGFVLPSAIINEISFTTKVPQKYENENVETVTKQAILNGSIVKESTEAHGTIQTEKVDEVIKEWEGSFFKDNPRLRK

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for VEZF1-KRT222

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for VEZF1-KRT222

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner

Gene

UniProtAcc

DrugBank ID

Drug name

Drug activity

Drug type

Drug status

Top

Related Diseases for VEZF1-KRT222

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source